Literature DB >> 2116161

Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.

D K Robbins1, P J Wedlund, R Kuhn, R J Baumann, R H Levy, S L Chang.   

Abstract

The effect of valproic acid (VPA) on the disposition of carbamazepine-10,11-epoxide (epoxide) was studied in five epileptic patients on chronic carbamazepine (CBZ) therapy. The individual pharmacokinetic parameters influencing epoxide disposition were determined in the presence and absence of VPA. VPA significantly decreased the clearance of unbound epoxide (an in vivo index of epoxide hydrolase activity), but did not appear to affect epoxide formation. VPA also increased the free concentrations of both CBZ and epoxide.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2116161      PMCID： PMC1380179          DOI： 10.1111/j.1365-2125.1990.tb03698.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  Quantitation of trans-10,11-dihydroxy-10,11-dihydrocarbamazepine in human urine by high-performance liquid chromatography.

Authors:  D K Robbins; S L Chang; R J Baumann; P J Wedlund
Journal:  J Chromatogr       Date:  1987-03-20

2.  The effect of storage conditions on the stability of carbamazepine and carbamazepine-10,11-epoxide in plasma.

Authors:  E Mendez-Alvarez; R Soto-Otero; G Sierra-Marcuño
Journal:  Clin Chim Acta       Date:  1986-02-15       Impact factor: 3.786

3.  Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.

Authors:  B M Kerr; A E Rettie; A C Eddy; P Loiseau; M Guyot; A J Wilensky; R H Levy
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

4.  Carbamazepine/valproic acid interaction in man and rhesus monkey.

Authors:  R H Levy; T A Moreland; P L Morselli; M Guyot; A Brachet-Liermain; P Loiseau
Journal:  Epilepsia       Date:  1984-06       Impact factor: 5.864

5.  Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro.

Authors:  G Tybring; C von Bahr; L Bertilsson; H Collste; H Glaumann; M Solbrand
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

6.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

7.  Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

Authors:  M J Brodie; G Forrest; W G Rapeport
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.

Authors:  F Pisani; A Fazio; G Oteri; E Spina; E Perucca; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

9.  Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide.

Authors:  T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

10.  Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma.

Authors:  L McKauge; J H Tyrer; M J Eadie
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681
  10 in total
  8 in total

Review 1.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 2.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 3.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.

Authors:  M Marchand; E Fuseau; D J Critchley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-02       Impact factor: 2.745

5.  Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.

Authors:  F Pisani; A Fazio; C Artesi; G Oteri; E Spina; T Tomson; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 6.  Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  The expression of human microsomal epoxide hydrolase is predominantly driven by a genetically polymorphic far upstream promoter.

Authors:  Xi Yang; Shun-Hsin Liang; Denise M Weyant; Philip Lazarus; Carla J Gallagher; Curtis J Omiecinski
Journal:  J Pharmacol Exp Ther       Date:  2009-04-13       Impact factor: 4.030

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.